Live Analyst Rating Changes 36623 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Uy Ear
MIZU

Uy Ear

Mizuho Securities
Wall Street Analyst
★★★☆☆
#1485
on 13Foresight · ranked by our own returns
43%
Success Rate
+5.6%
Average Return
27 of 63 calls profitable · +3.4% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 43% of Uy Ear's ratings turned a profit when each position was held for 1 year — averaging +5.6% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

112 Buy 19 Hold 0 Sell
Uy's Stock Coverage 17 ratings · 2026-10-04
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
QTTB
Q32 Bio
 Sep 15, 2026 HOLD Strong Buy
+575.0% avg upside
28 analysts
 — -17.4% ·
TECX
Tectonic Therapeutic
 Sep 15, 2026 HOLD Strong Buy
+141.0% avg upside
24 analysts
 — -20.9% ·
ARQT
Arcutis Biotherapeutics
 Sep 15, 2026 HOLD Strong Buy
+60.4% avg upside
14 analysts
 — +7.6% ·
INAB
IN8bio
 Sep 15, 2026 HOLD Strong Buy
+5636.3% avg upside
5 analysts
 — +14.3% ·
MBX
MBX Biosciences, Inc.
 Sep 15, 2026 HOLD Strong Buy
+44.3% avg upside
14 analysts
 — -4.2% ·
QURE
uniQure
 Sep 15, 2026 HOLD Strong Buy
+146.8% avg upside
30 analysts
 — -43.9% ·
RLMD
Relmada Therapeutics
 Sep 15, 2026 HOLD Buy
+271.2% avg upside
15 analysts
 — -18.9% ·
RNAC
Cartesian Therapeutics
 Sep 15, 2026 HOLD Strong Buy
+321.9% avg upside
19 analysts
 — -6.1% ·
SLGL
Sol-Gel Technologies
 Sep 15, 2026 HOLD Strong Buy
+9.2% avg upside
6 analysts
 — +11.8% ·
EOLS
Evolus
 Sep 15, 2026 HOLD Strong Buy
+96.2% avg upside
9 analysts
 — +140.7% ·
ACAD
ACADIA Pharmaceuticals
 Sep 15, 2026 HOLD Strong Buy
+80.0% avg upside
43 analysts
 — -24.1% ·
SRPT
Sarepta Therapeutics
 Sep 15, 2026 HOLD Buy
+244.8% avg upside
50 analysts
 — -9.9% ·
ALKS
Alkermes
 Sep 04, 2026 BUY Strong Buy
+5.1% avg upside
34 analysts
$65.00
55.62% Upside
 -12.1% ·
NBIX
Neurocrine
 Dec 12, 2025 HOLD Strong Buy
+30.4% avg upside
37 analysts
$175.00
22.32% Upside
 -7.9% ·
OCGN
Ocugen
 Aug 18, 2023 HOLD Strong Buy
+806.8% avg upside
17 analysts
 — +180.5% ·
CABA
Cabaletta Bio
 Aug 11, 2023 HOLD Strong Buy
+611.9% avg upside
16 analysts
 — -69.5% ·
IRWD
Ironwood Pharma
 Jul 10, 2019 HOLD Buy
+226.4% avg upside
23 analysts
$14.00
284.69% Upside
 -6.7% ·
🔒 12 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Uy Ear — Frequently Asked Questions
How accurate are Uy Ear's stock ratings?
Based on the calls 13Foresight could measure, about 43% of Uy's ratings were profitable over a one-year hold, with an average return of +5.6% per rating, or +3.4% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Uy ranked on 13Foresight?
Uy Ear is currently ranked #1485 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Uy cover?
Uy most recently has ratings on QTTB, TECX, ARQT, INAB, MBX, QURE, RLMD, RNAC, SLGL, EOLS, ACAD, SRPT and 5 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.